Adaptimmune Therapeutics PLC
ADAPHealthcare · Biological Products, (No Diagnostic Substances) · X0 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $178.0M | $60.3M | $27.1M | $6.1M | $4.0M | $1.1M |
| Operating income | −$68.8M | −$139.7M | −$164.0M | −$162.2M | −$133.4M | −$139.8M |
| Net income | −$70.8M | −$113.9M | −$165.5M | −$158.1M | −$130.1M | −$137.2M |
| Total assets | $246.0M | $282.6M | $328.9M | $469.5M | $451.1M | $181.5M |
| Total liabilities | $234.1M | $243.1M | $247.0M | $263.6M | $109.9M | $57.9M |
| Equity | $11.8M | $39.5M | $81.9M | $206.0M | $341.2M | $123.6M |
| EPS (diluted) | $-0.05 | $-0.09 | $-0.17 | $-0.17 | $-0.15 | $-0.22 |
| Shares out. | 1.48B | 991.8M | 940.4M | 930.8M | 780.5M | 628.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −38.6%
- Net margin
- −39.8%
- Return on equity
- −597.6%
- Return on assets
- −28.8%
- Return on capital (ROCE)
- −37.9%
- Liabilities / assets
- 95.2%
- Debt / equity
- 19.76×
- Book value / share
- $0.01
- Revenue growth (YoY)
- 195.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -13.03distress
- Accruals / assets
- 1.0%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 1, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Long Focus Capital Management, LlcPassive (13G)Feb 17, 2026
- Two Seas Capital LpPassive (13G)Nov 14, 2025
- New Enterprise Associates 14, L.P.Activist (13D)Aug 19, 2025
- Ecor1 Capital, LlcPassive (13G)Aug 19, 2025
- Baillie Gifford & CoPassive (13G)Feb 12, 2025
- Matrix Capital Management Company, LpPassive (13G)Jan 8, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Oct 15, 2025 | 31.4M | 1.0 | +5.8% |
| Sep 30, 2025 | 29.6M | 1.0 | +28.6% |
| Sep 15, 2025 | 23.1M | 1.0 | -8.3% |
| Aug 29, 2025 | 25.1M | 1.0 | +127.1% |
| Aug 15, 2025 | 11.1M | 1.0 | +32.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard notice · Regulation FD disclosureOct 20, 2025
- Delisting / listing-standard noticeSep 26, 2025
- Delisting / listing-standard noticeSep 12, 2025
- Director / officer changeSep 8, 2025
- Director / officer changeAug 29, 2025
- Director / officer changeAug 15, 2025
- Delisting / listing-standard noticeAug 14, 2025
- Results of operationsAug 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- RWApr 22, 2026
- SCHEDULE 13GFeb 17, 2026
- EFFECTNov 14, 2025
- SCHEDULE 13G/ANov 14, 2025
- 424B3Nov 13, 2025
- 15-12GNov 13, 2025
- S-8 POSOct 28, 2025
- S-8 POSOct 28, 2025
- S-8 POSOct 28, 2025
- POS AMOct 28, 2025
- 25FORM 25Oct 28, 2025
- 8-KOct 20, 2025
- 3OWNERSHIP DOCUMENTOct 8, 2025
- 8-KSep 26, 2025
- 8-KSep 12, 2025